Nemours Receives $5.32 Million NIH Sickle Cell Grant

The five-year federal award funds the third phase of the Delaware Comprehensive Sickle Cell Research Center.

Updated on Nov. 19, 2026 in Business

Isometric editorial illustration of a row of amber-tinted sample vials in a wooden rack on a pale laboratory bench, representing sickle cell disease research funding.
Nemours Children's Health received a five-year, $5.32 million National Institutes of Health grant to fund the third phase of its Delaware Comprehensive Sickle Cell Research Center. AI Illustration. Upload story photo >

Nemours Children's Health has received a five-year, $5.32 million grant from the National Institutes of Health to support sickle cell disease research. The funding powers the third phase of the Delaware Comprehensive Sickle Cell Research Center.

Why it matters

The grant extends a sustained line of federal support for sickle cell research in Wilmington, following earlier awards of $10.2 million in 2014 and $10.5 million in 2021. Continued funding allows the center to pursue studies on therapies and disease complications in the region's pediatric population.

The $5.32 million award is a five-year NIH grant, a figure that sits below the $10.5 million awarded in 2021 for the same research program. The total number and scope of the one-year pilot projects it will fund beyond the "up to eight" ceiling remain unspecified.

The players

Nemours Children's Health

A pediatric health system headquartered in Wilmington, Delaware, that operates hospitals and research programs serving children across the Delaware Valley.

National Institutes of Health

The primary federal agency for biomedical and health research, which awards grants to universities and medical institutions nationwide.

The details

The grant funds the third phase of the Delaware Comprehensive Sickle Cell Research Center, led by David Brousseau, MD, and Robin Miller, MD. It supports up to eight one-year pilot projects and expanded use of bioinformatics, building on earlier work on sickle cell therapies among adolescents and young adults and on blood vessel damage linked to the disease.

Timeline

  1. 2014: Nemours receives a $10.2 million NIH sickle cell grant.

  2. 2021: Nemours receives a $10.5 million NIH sickle cell grant.

  3. Third quarter of 2026: Nemours receives over $10 million in separate NIH research funding.

  4. November 19, 2026: Becker's reports the five-year $5.32 million grant.

Healthcare Research Funding

The renewal reflects the NIH's Sickle Cell Disease Research Centers program, which has repeatedly funded multi-phase centers rather than one-time projects. Its third-phase award to Nemours places Delaware's center within that sustained federal investment in sickle cell research.

For families in the Wilmington area living with sickle cell disease, continued center funding supports ongoing clinical research and pilot studies at Nemours. The grant does not change current treatment access, and the specific pilot projects and their timelines have not yet been announced.

The takeaway

Sustained federal grants like this one show how multi-phase research programs can build over time, with each award expanding on prior findings. Readers tracking sickle cell care should watch for announcements of the pilot projects this funding will support.

Further reading

For related coverage, explore Healthcare reporting on research funding and clinical programs in the Wilmington area.

Source note: This article includes information reported by Becker's Hospital Review | Healthcare News & Analysis.